Alteogen Reveals Sanofi as First ALT-B4 License Partner
Non-Exclusive $1.373 Billion Deal Signed in 2019
SC Formulation Conversion Platform Expands to Eight Global Big Pharma Companies
On June 18, Alteogen revealed that its first licensing partner for the subcutaneous (SC) formulation conversion using ALT-B4, based on the Hybrozyme® platform signed in 2019, is Sanofi.
In November 2019, Alteogen entered into a non-exclusive license agreement for ALT-B4 with one of the world’s top 10 pharmaceutical companies, announcing a total deal value of 1.373 billion dollars. At the time, the partner’s name was kept confidential in accordance with the terms of the agreement.
Alteogen’s Hybrozyme technology, starting with the agreement with Sanofi, has since led to licensing deals with eight global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo, Biogen, Sandoz, and Intas.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Tae Yeon Jeon, CEO of Alteogen, said, “By disclosing the partner, we are able to reaffirm the competitiveness of the ALT-B4 platform technology,” adding, “We expect that news of clinical development progress will further increase interest in ALT-B4.” He continued, “ALT-B4, which is being applied to various modalities such as monoclonal antibodies, bispecific antibodies, and ADCs, is providing fast and convenient administration options in multiple therapeutic areas, including oncology and autoimmune diseases, making its necessity increasingly evident.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.